HuLA immune Inc.

[On Demand]
Based on the “neo-self theory”, which is a drug discovery concept for autoimmune diseases protected by intellectual property, we identify therapeutic targets for autoimmune diseases and obtain therapeutic agents (antibodies) for those therapeutic targets. Obtain a non-clinical POC to verify the drug discovery concept using the obtained candidate antibody. We envision a business model for licensing out to pharmaceutical companies at this stage (preclinical stage). Research and development activities are already underway for the treatment of antiphospholipid antibody syndrome and type 1 diabetes, and at this point, we are mainly conducting activities to derive Hit candidates for antiphospholipid antibody syndrome.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Neo-self antibody titer test
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Professor (Deputy director of Immunology Frontier Research Center)
OSAKA University